News

Cambridge UK – 15 April 2020 – Healx, the AI-powered and patient-inspired tech company specialising in accelerating the discovery and development of rare disease treatments, today announced a partnership with US and Europe-based patient group Children’s Tumor Foundation (CTF) to progress new AI-derived therapies for neurofibromatosis (NF).

Cambridge, UK, 14 April 2020: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced special commercial licensing terms to facilitate rapid access to its cGMP-compliant CHOSOURCE™ platform for the development or production of therapeutic proteins, diagnostic assay components or vaccines relating to COVID-19.

Applications for Accelerate@Babraham, designed to support early stage life science ventures, will close on June 17th 2020.


The Accelerate@Babraham initiative is designed to support ambitious early stage life science ventures. It does this by giving access to appropriate short-term open access laboratory and office space, facilitating interaction with the academic community at the Babraham Institute and providing access to our global network, including mentoring and business support.

Hints and Tips for Working from Home by george james ltd


Working from home is a new experience for many people, and even those of us who have worked at home on and off for many years have probably not done so for such an extended period. For some people working at home may become the new norm.


george james ltd have put together some hints and tips that we hope you find helpful.

Cambridge, UK: 14 April 2020: Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics, announces that Regeneron Pharmaceuticals Inc (“Regeneron”) has been unsuccessful in recent attempts to invalidate four of Kymab’s US patents covering genetically modified mice and the human antibody therapeutics produced from these mice. The patents are US patent numbers 9,434,782; 9,505,827; 9,447,177; and 10,165,763 known as the “Bradley Patents”.

New England Biolabs is working diligently to ensure we keep our employees and their families safe, while maintaining our business continuity in support of our many customers around the globe. Our manufacturing and distribution teams continue to be fully operational, and we are working closely with our suppliers and distribution partners to ensure uninterrupted access to our products and technical support. We are also following the guidelines of local and national health organizations in order to mitigate the spread of COVID-19.

The MagSi-NA Pathogens Kit from AMSBIO enables easy extraction of DNA and RNA from serum, plasma, oropharyngeal swab / nasopharyngeal swab, and any other respiratory samples for pathogen detection.

The kit is particularly suitable for total nucleic acid extraction for SARS-CoV-2 / COVID-19 detection, currently a major bottleneck in COVID-19 testing.

Dear Friends, Colleagues and Supporters of NHS staff,

We are seeking donations to the Cambridge China COVID-19 Collaboration (4C) Appeal which is an official part of the University of Cambridge COVID-19 appeal.

Cambridge, UK, 07 April 2020: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, today announced it has contributed to two new peer-reviewed papers under the U.S. Food and Drug Administration’s (FDA) CiPA (Comprehensive in vitro Proarrhythmia Assay) initiative. The papers, in Nature Scientific Reports1 and Toxicology and Applied Pharmacology2, focus on application of improved cardiac safety testing protocols and recommendations for best practice for the drug discovery industry.

Westbury, NY – Apr. 6, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced the opening of its new blood donor center on the Tufts University campus in Medford, MA to support academic and pharmaceutical researchers involved in COVID-19, cell and gene therapy research.

Pages